John Paulson Biocryst Pharmaceuticals Inc Transaction History
Paulson & Co. Inc.
- $1.65 Billion
- Q4 2024
Shares
2 transactions
Others Institutions Holding BCRX
# of Institutions
279Shares Held
169MCall Options Held
930KPut Options Held
1.03M-
Vanguard Group Inc Valley Forge, PA21.9MShares$198 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$181 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$107 Million1.3% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.09MShares$82.2 Million4.33% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY8.14MShares$73.7 Million1.52% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.68B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...